$4.54
0.040.89%
Last update: Nov 6, 7:59 PM
Lexaria Bioscience Corp
LEXXNASDAQ
Lexaria Bioscience fell 72.7% from $16.65 to $4.54, behind the S&P 500's +10.5%. Its worst day was Sep 10 (−37.0%), and its low came Oct 19 at $2.60.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.95 beat the $-2.40 estimate on $174,000.00 revenue (est. $70,000.00).
−2.7% · S&P 500 +0.5%
Lexaria Bioscience closed at its highest level of the year, 20.7% above where the year started.
Story events cover the past 12 months · Times ET
+8.9% · S&P 500 −1.1%
EPS of $-1.05 beat the $-1.20 estimate on $0.00 revenue (est. $70,000.00).
+5.1% · S&P 500 −0.2%
EPS of $-0.90 beat the $-1.20 estimate on $20,000.00 revenue (est. $70,000.00).
+7.8% · S&P 500 +1.0%
Lexaria Bioscience shares fell 21.9%, while the S&P 500 fell 0.0%.
−21.9% · S&P 500 0.0%
EPS of $-1.20 missed the $-0.90 estimate on $0.00 revenue (est. $20,000.00).
−1.3% · S&P 500 +0.4%
Lexaria Bioscience shares fell 25.2%, while the S&P 500 rose 1.7%.
−25.2% · S&P 500 +1.7%
Today’s announcement is separate from, and has no relationship with, Lexaria’s pre-existing Material Transfer Agreement with another pharmaceutical company.The MTA details the conditions under which PegBio will
+32.4%, the year's best day · S&P 500 +0.7%
Lexaria Bioscience shares fell 37.0%, while the S&P 500 fell 0.6%.
−37.0%, the year's worst day · S&P 500 −0.6%
Lexaria Bioscience closed at its lowest level of the year, 84.4% below where the year started.
−9.1% · S&P 500 +0.4%
Where it ended: a close of $4.54 on Nov 9, 2026. Up next: Q4 2026 earnings on Nov 27, 2026 (EPS est. $-0.90, revenue est. $20,000.00).
Nothing in the past 12 months.
All LEXX dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for LEXX and SPY from Benzinga historical bars. Not investment advice.
